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Abstract
Triosephosphate isomerase (TPI) deficiency is a fatal genetic disorder characterized by
hemolytic anemia and neurological dysfunction. Although the enzyme defect in TPI
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was discovered in the 1960s, the exact etiology of the disease is still debated. Some
aspects indicate the disease could be caused by insufficient enzyme activity, whereas
other observations indicate it could be a protein misfolding disease with tissue-specific
differences in TPI activity. We generated a mouse model in which exchange of a con-
served catalytic amino acid residue (isoleucine to valine, Ile170Val) reduces TPI spe-
cific activity without affecting the stability of the protein dimer. TPIIle170Val/Ile170Val
mice exhibit an approximately 85% reduction in TPI activity consistently across all
examined tissues, which is a stronger average, but more consistent, activity decline than
observed in patients or symptomatic mouse models that carry structural defect mutant
alleles. While monitoring protein expression levels revealed no evidence for protein
instability, metabolite quantification indicated that glycolysis is affected by the active
site mutation. TPIIle170Val/Ile170Val mice develop normally and show none of the disease
symptoms associated with TPI deficiency. Therefore, without the stability defect that
affects TPI activity in a tissue-specific manner, a strong decline in TPI catalytic activity
is not sufficient to explain the pathological onset of TPI deficiency.
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1 | INTRODUCTION
Triosephosphate isomerase (TPI) deficiency was among the
first human genetic disorders discovered by systematic enzy-
mological screens more than 60 years ago.1 The syndrome is
characterized by severe progressive neuromuscular degener-
ation (often manifesting as early as the first 7 months of
life), neurologic dysfunction that is associated with impaired
synaptic vesicle dynamics, hemolytic anemia and associated
susceptibility to infections, and episodic hypotonia.2-4 Typi-
cally, patients are severely and systemically affected and do
not reach the age of five. A noticeable exception are two
brothers of Hungarian origin who have a milder form of the
disease (caused by a unique compound-heterozygous
genotype).2
TPI deficiency is recessively inherited and caused by
pathogenic genetic variants that alter the coding sequence of
the TPI1 gene on chromosome 12q19.4,5 The native TPI
enzyme is present as a 2× 27 kDa homodimer and fulfills an
essential metabolic function by catalyzing the interconversion
of the three carbon sugar phosphates, glyceraldehyde
3-phosphate (Ga3P) and dihydroxyacetone phosphate
(DHAP), in glycolysis.6 A substantial reduction of enzymatic
activity is reported in all TPI deficient patients, as well as an
accumulation of the TPI substrate, DHAP, indicating that gly-
colytic flux is affected.4 Reduced glycolytic flux and conse-
quent energy disturbance, alterations in lipid metabolism, and
the interconversion of DHAP to toxic methylglyoxal and con-
sequent increase in oxidative stress have been discussed as
biochemical causes for, or at least contributors to, TPI defi-
ciency.4,7,8 Such features would be consistent with a typical
metabolic enzymopathy, defined as the biochemical conse-
quences of reduced enzymatic activity.
However, other observations are in conflict with the typi-
cal enzymopathy hypothesis. First, TPI is considered the
“least rate limiting” enzyme of glycolysis, with only a frac-
tion of its in vitro activity required to enable sufficient gly-
colytic flux to sustain normal cellular function.9 Hence, it is
not clear if the partial loss of TPI enzyme activity would
phenotypically penetrate and explain the disease symptoms.
In parallel, it was noted early on that the population fre-
quency of heterozygous TPI deficient alleles is higher than
the actual disease prevalence would predict.10-14 The litera-
ture proposed two hypotheses to explain this discrepancy.
The first suggests an evolutionary advantage of being a het-
erozygous carrier, which would maintain a higher frequency
of heterozygote carriers in a population.15 The second possible
explanation is that only a subset of the alleles that reduce TPI's
enzyme activity induce disease, while other allelic combina-
tions, although reducing the activity to a similar extent, would
not result in a clinical disease. Thus far, a heterozygote advan-
tage of TPI deficient alleles could not be substantiated. For
instance, in a large survey of centenarians, TPI deficient alleles
were neither enriched nor diminished.16 Instead, the TPI
2 SEGAL ET AL.
deficient patients discovered to date are consistent with the
alternative hypothesis that only some of the deficient alleles
cause TPI deficiency. Indeed, while many mutations could
hypothetically affect TPI's enzymatic activity, symptomatic
penetrance in the homozygous state is only seen for a single
allele, a G-C transversion in codon 104, which causes a con-
served residue exchange from glutamic acid to aspartic
acid.4,5,17-20
The Glu104Asp amino acid substitution is located in the
dimer interface and does not directly influence the catalytic
function of TPI; transgenic yeast models expressing the
allele show catalytic functionality but revealed altered affini-
ties of the TPI dimer subunits in vivo.21 A crystal structure
revealed the reduced dimer stability caused by the
Glu104Asp substitution is explained by the disruption of an
elaborate conserved network of buried water molecules that
bridge the two subunits.20
A few years ago our research revealed interesting fea-
tures of another allele, TPIIle170Val. The TPIIle170Val allele
is associated with TPI deficiency only in a compound-
heterozygous context, that is, disease-causing only in
combination with the common pathological allele,
TPIGlu104Asp, and hence, not of major clinical relevance.17
However, the TPIIle170Val allele results in a direct reduc-
tion in catalytic activity due to the exchange of a con-
served catalytic residue. Purified TPIIle170Val shows
approximately 5% activity compared to wild type TPI
in vitro resulting from changes in the key enzyme parame-
ters, with an altered affinity for the substrate.22 However,
this variant leaves the TPI dimer interface and secondary
structure intact. The purified TPIIle170Val enzyme is fully
folded and shows similar stability to wild type TPI alleles
in vitro, according to CD spectroscopy.22 Due to the differ-
ence between the TPIIle170Val allele and the common patho-
genic allele, TPIGlu104Asp, in terms of catalytic activity and
structural stability, the TPIIle170Val mutant allele allows for the
design of experiments that can disentangle the consequences
of protein stability from those of a catalytic defect.
When introduced into Drosophila and paired with a TPI
null allele, the human TPIIle170Val causes behavioral dys-
function in response to thermal and mechanical stress, symp-
toms that have been related to TPI deficiency.23 However, in
other Drosophila models, TPI deficiency-like phenotypes
have also been induced by catalytically functional alleles in
which reduced TPI deficiency is associated with dimer inter-
face mutations or reduced protein stability. Two Drosophila
mutant lines discovered in parallel named sugar kill and
wasted away24,25 carry the same recessive hypomorphic TPI
allele: a methionine to threonine substitution at the dimer
interface (residue 80). The allele affects the stability of the
protein, resulting in reduced TPI activity and neurological
symptoms reminiscent of the human disease. Roland et al
obtained a surprising result upon expressing the sugar kill
allele in combination with a catalytically inactive TPI mutant
allele, TPIMet11Lys.26 This compound heterozygous mutant
was rescued from the behavioral and longevity phenotypes
observed in the sugar kill homozygotes without restoring the
overall TPI activity. Hence, in this particular model, it is not
TPI activity but the degradation of the protein that causes all
symptoms. Because of these contrasting observations in the
various Drosophila models—a similar set of phenotypes is
observed dependent and independent of a reduction in TPI
specific activity—the Drosophila models remained inconclu-
sive about the main cause of TPI deficiency.
The answer to the disease etiology question is not provided
by two mouse models either. One of these carries an aspartate
to glycine substitution at codon 49, positioned in the dimer
interface,27 and a second has a phenylalanine to serine substitu-
tion at amino acid 57,28 which affects the stability of the pro-
tein and leads to its degradation. Both mouse models
recapitulate the key symptom of TPI deficiency, hemolytic ane-
mia, but, as they also both combine a stability defect with a
decline in TPI activity that penetrates in a tissue-specific man-
ner, they do not enable the distinguishing of the consequences
of activity decline from structural defect.
We speculated that the mouse models are compatible
with a third hypothesis for explaining the etiology of TPI
deficiency. In both models, TPI enzymatic activity varied
greatly between tissues, with lowest activities to be mea-
sured in tissues, like brain, that were the most affected in
patients. Hence, it was possible that the syndrome is caused
by tissue-specific activity differences. The symptoms would
be caused by a TPI activity that falls below a pathological
threshold in some tissues, while viability is maintained by
sufficient TPI activity in other tissues.
In order to address this problem, we created a complemen-
tary mouse model in which we introduced the TPIIle170Val
allele by site-directed mutagenesis, reducing enzyme activity
but leaving the dimer interface and protein stability unaf-
fected. The C57BL/6J-based animals have a approximately
15% residual TPI activity consistently in all examined tissues,
which is a much stronger average activity decline than mea-
sured in human patients or the previous animal models of TPI
deficiency. Without the tissue-specific differences in TPI
activity, TPIIle170Val/Ile170Val animals develop normally and
show no signs of hemolytic anemia, neurological dysfunction,
no major immune deficiency, motor neuron symptoms nor
signs of metabolic syndrome—the phenotypes associated with
the human disorder. Hence, in the absence of the protein sta-
bility defect that produces tissue-specific TPI activity differ-
ences, a decline in TPI activity is not sufficient to cause
symptoms of TPI deficiency.
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2 | RESULTS
2.1 | TPIIle170Val/Ile170Val mice show a strong
reduction in TPI activity uniformly across all
examined tissues
In order to introduce the TPIIle170Val mutation to mice, we
cloned the mouse TPI1 locus into an Escheria coli vector
(pTREtight2, Addgene #19407), introduced the ATT to GTT
transition by PCR mutagenesis and inserted a loxP-flanked
neoR cassette into the NheI site into TPI1 intron 5 (Figure 1A).
The vector was then used to generate TPIIle170Val/Ile170Val mice
(Methods section, Figure 1B,C for an exemplary genotyping
of an F1 litter). The mice were backcrossed for nine genera-
tions to C57BL/6J wild type animals.
FIGURE 1 TPIIle170Val/Ile170Val mutation causes a reduction in enzymatic activity and affects glycolysis in vivo. A, Schematic diagram of the
Escheria coli vector used for the generation of TPI deficient mouse, to introduce a mutation of residue 170 located in exon 5 of the Tpi1 locus. B, Example
genotyping of heterozygous (lane 4, 6, 8 “+/−”) and wild-type (lane 5, 7, 9, “+/+”) littermates. C, Example sanger sequencing traces of the TPI locus of
three heterozygous littermates. D, TPI activity of tissue lysates of TPIIle170Val/Ile170Val animals shown relative to wild-type activity. Data are represented as
mean ± SD of three independent experiments. E, Western blot to assess TPI protein levels in lysates from wild type and TPIIle170Val/Ile170Val animals. Blots
show representative example of three biological repeats. Membranes stained with Ponceau-S stain to show protein loading (F and G). Relative
concentrations of the TPI substrates, DHAP and Ga3P, in extracts from wild type and TPIIle170Val/Ile170Val tissues determined by LC–MS/MS. Bars
represent mean ± SD. P values shown only for significant differences (P < .05) between genotypes, calculated by Student's t test
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We measured the TPI activity of the TPIIle170Val/Ile170Val
mouse. While total TPI activities differ greatly between tis-
sues, the TPIIle170Val/Ile170Val allele penetrates similarly
across tissues in relative terms. In kidney, liver, brain, heart,
lung, spleen, and blood, TPIIle170Val/Ile170Val mice exhibited
about approximately 13% of total TPI activity compared to
wild-type animals (Figure 1D). This differs to the dimer
interface mutants that exhibit substantial tissue differences in
the relative penetrance of the enzyme defect.28,29 In yeast, a
partial compensation of TPI activity correlates with an
upregulation of the enzyme protein level.22 However, in
mice, no significant upregulation of the protein level was
observed (Figure 1E). Consequently, the moderate increase
of total TPI activity when comparing in vitro and in vivo
experiments might be explained by post-translational or met-
abolic regulation of TPI activity.
2.2 | Substrate accumulation in
TPIIle170Val/Ile170Val mice
Using mass spectrometry, we determined the concentrations
of the TPI substrates, DHAP and Ga3P, in lysates of brain,
liver and skeletal muscle of wild type and TPIIle170Val/Ile170Val
mice. Glucose metabolism was altered in the
TPIIle170Val/Ile170Val mice: we detected an increased level of
the TPI substrate, DHAP, most strikingly in brain tissue
(Figure 1F,G). These findings are consistent with the human
disease in which patients are found to have high blood levels
of DHAP.4 Ga3P levels are also elevated in liver and skeletal
muscle of TPIIle170Val/Ile170Val mice. (Ga3P levels in brain tis-
sues of wild type and TPIIle170Val/Ile170Val mice were below
the level of quantification.)
2.3 | TPIIle170Val/Ile170Val mice show no
phenotypes associated with TPI deficiency
TPIIle170Val/Ile170Val mice were analyzed in a phenotypic
screen. Sixty animals (15 male and 15 female, both wild
type C57BL/6J and TPIIle170Val/Ile170Val), all born from het-
erozygous crosses within 2 weeks, underwent systematic
phenotyping.30-32 The systematic study revealed that, despite
their substantial reduction in TPI activity, the animals dis-
play none of the phenotypes associated with TPI deficiency
(summary of full screen can be found in supp. table 1).
First, since TPI deficiency in humans is associated with
progressive neuromuscular impairment, we assessed muscle
FIGURE 2 TPIIle170Val/Ile170Val
mice show no signs of neurological,
muscular, or cardiovascular
alterations. Bars represent mean
± SD. P values shown only for
significant differences (P < .05)
between genotypes, calculated by
Student's t test. A, Grip strength
measured by a force meter on a
mounted grid. Values shown relative
to body weight. B, Balance measured
using a rotarod. Mean latency to fall
calculated over three trails. C, Body
weight of wild type and
TPIIle170Val/Ile170Val mice. D,
Percentage lean mass calculated by
qNMR. (E and F) Heart rate and
respiration rate measured by
echocardiogram
SEGAL ET AL. 5
function by measuring grip strength (Figure 2A). No signifi-
cant differences were detected. Testing motor coordination
with an accelerating rotarod also did not give any hints towards
a neurological phenotype (Figure 2B). Body composition anal-
ysis revealed no indication of muscle wasting (Figure 2C,D).
Because of muscle weakness, TPI deficient patients present
with breathing and heart problems. However, we observed no
significant difference in heart rate and respiration rate in
TPIIle170Val/Ile170Val male and female mice (Figure 2E,F).
Some TPI deficient patients develop additional neurolog-
ical symptoms, including intellectual disability. We chal-
lenged the TPIIle170Val/Ile170Val mice in behavioral tests
sensitive to certain changes in central nervous system func-
tion (hot-plate, open field, and prepulse inhibition) but found
no differences of note (Figure 3).
Similar results were obtained for hematology. Although
hemolytic anemia is a main pathologic feature of TPI defi-
ciency and the common characteristic of two mouse models
that possess TPI alleles with structural defects,27,28 there was
no indication for such in the TPI active site mutant animals.
In general, the data obtained did not provide evidence of any
significant effect of the genotype on parameters measured
(Figure 4A-E). We examined the spleen and liver to detect
any signs of hemolytic anemia, which is characterized by
splenomegaly and reticulocytosis (increased production and
circulation of reticulocytes), and often an enlarged liver. We
observed a slight decrease in spleen size in female
TPIIle170Val/Ile170Val mice, which is not consistent with hemo-
lytic anemia (for which an increase in spleen size would is
expected in most cases) and no difference in liver weight
(Figure 4D,E). For better visualization of reticulocytes, we
performed H&E staining and TER-119 immunohistochemis-
try. The TER-119 antibody reacts with cells of the erythroid
lineage from the early erythroblast through mature erythro-
cyte stages in the red pulp of spleen.33 However, we
detected no histological differences between mutant and
control mice and observed no signs of increased reticulocyte
production in the red pulp (Figure 4F-I).
TPI deficient patients reportedly have a severely increased
risk of infection. Therefore, we studied immunological param-
eters in TPIIle170Val/Ile170Val mice. The analysis of the propor-
tions of leukocyte subsets in TPI mutant mice and littermate
FIGURE 3 TPIIle170Val/Ile170Val mice display normal sensory and motor function. A and B, Bars represent mean ± SD. P values shown only
for significant differences (P < .05) between genotypes, calculated by Student's t test. A, Mice tested on a hot plate and observed for the time taken
to respond to heated surface of male and female mice pooled. B, Locomotor activity (total distance traveled) in the open field test of male and
female mice pooled. C, Acoustic startle response measured over a series of increasing sound pressure stimulus volume. n = 15, mean ± SD
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controls did not give evidence for a TPI-related impaired leu-
kocyte development (Figure 4J-M). In addition, the measure-
ment of basal immunoglobulin levels revealed similar basal
immunoglobulin concentrations and a similar isotype distribu-
tion in mutants compared to controls (Figure 4N,O).
3 | DISCUSSION
We have presented a mouse model that clarifies key missing
aspects about the biochemical etiology of TPI deficiency, a
severe, genetic metabolic disease known since the 1960s.
FIGURE 4 Clinical
readouts of hemolytic anemia
and associate immunodeficiency
did not indicate pathology in
TPIIle170Val/Ile170Val mice. A-E,
Bars represent mean ± SD.
P values shown only for
significant differences (P < .05)
between genotypes, calculated by
Student's t test. A-C, Red blood
cells, mean corpuscular volume
and mean corpuscular
hemoglobin calculated by abc-
Vet hematology analyzer. D
and E, Liver and spleen weight.
F and G, Representative images
of spleens probed with TER119
antibody to stain the erythroid
lineage. H and I, H&E staining
of representative spleens. J-M,
Example cell populations in
peripheral blood measured by
flow cytometry and shown as a
proportion of leukocytes (CD45
+). Bars represent mean ± SD.
P values shown for significant
differences (P < .05) between
genotypes, calculated by
Student's t test. N and O,
Immunoglobulin levels measured
in plasma from male and female
mice by multiplex analysis, P,
Scheme: suggested model for the
etiology of TPI deficiency
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The active site mutation of the TPI gene reduces the catalytic
activity of the enzyme to approximately 13% of in vivo
activity (Figure 1), which is a much more severe reduction
in activity than observed in patients. Without affecting pro-
tein stability, the reduction in TPI activity was detected, in
relative terms, uniformly across all examined tissues. This
strong reduction in activity does not induce any disease
symptoms associated with human TPI deficiency, including
hemolytic anemia, neurological dysfunction, or shortened
lifespan.4,21,27 As disease symptoms amplify in humans with
age, we also investigated 2-year old mice, but could not
detect any notable phenotypes at this age either.
An important implication of our findings impacts drug
development, which could focus on stabilizing the TPI
enzyme structure and may not necessarily need to restore
TPI enzymatic activity. Developing a drug that would repli-
cate the complicated chemistry of the TPI enzymatic reac-
tion is challenging by nature. Conversely, designing drugs
that increase protein stability is an easier task. The latter can
be achieved with molecules that show affinity to the protein,
without necessarily needing to be metabolized or affect the
highly optimal catalytic site of TPI.34,35 We believe that
aiming for the development of a TPI protein stabilizing
agent would increase the chance of finding a suitable disease
therapy.
Furthermore, our results suggest that in the diagnosis of
TPI deficiency, enzyme activity measurements alone could
be a poor predictor of disease penetrance. Nevertheless, we
would like to stress that our results should not be mis-
interpreted as a claim that reduced TPI enzymatic activity, in
itself, can be excluded as a contributing factor to the disease
symptoms, nor that the sole cause of the disease symptoms
must be a result of loss of an unknown second function or a
new cellular problem caused by the TPI mutations. For
instance, one study suggested that TPI deficiency could be
caused by aggregation of the TPI protein.7 Per se, our mouse
model does not contradict this hypothesis; however, it is also
not confirmatory. Indeed, observations made with rare
compound-heterozygous cases imply that, although reduced
TPI activity may not be sufficient to cause the disease symp-
toms, a reduced activity is required for penetrance: the rare
compound-heterozygous cases carry one allele with the
enzyme dimerization defect (TPIGlu104Asp) and another allele
that only reduces enzyme activity (eg, TPIIle170Val).17 In
these cases, the allele with reduced TPI activity is not able to
compensate for the Glu104Asp allele, whereas, a wild-type
allele would. Conversely, when the Glu104Asp allele is het-
erozygous with a catalytically active pathological allele, the
disease pathology does not penetrate to the same extent and
results in a milder form of the disease.2 Such patterns of pen-
etrance indeed point to a lack of TPI enzymatic activity to
be the key disease causing agent.
These seemingly contradictory findings might be explained
if one considers tissue specific factors. A previous mouse
model of TPI deficiency, based on the dimer interface-located
residue mutation (methionine to threonine at residue 80),
showed an average of approximately 35% loss of TPI activity.
However, the activity ranged from approximately 55% in kid-
ney to approximately 13% in brain.29 Similarly, a second
mouse model of TPI deficiency, based on a mutation that also
affects TPI protein stability, showed a range of activities in the
tissues tested, from 48% in skeletal muscle to 10% in red blood
cells.28 Conversely, the active site mutation of the TPIIle170Val
allele penetrate—in relative terms—similarly across all tissues
examined (Figure 1D). Hence, an intuitive explanation is that
TPIIle170Val/Ile170Val mice are symptomless, as in each tissue a
critical amount of TPI activity is reached, while in the (patho-
logical) dimer interface mutants, in some tissues, TPI activity
falls below the pathological threshold. Indeed, in the related
metabolic disorder, ribose-5-phosphate isomerase (RPI) defi-
ciency, tissue-specific differences in the penetrance of the
enzyme defect are considered to be the cause of the disease.
Mutations that cause such tissue-specific activity differences
are far less likely to occur compared to null alleles, and, as a
result, RPI deficiency is among the rarest genetic diseases
known.36,37 Thus, structural and metabolic defects can interact
in a tissue-specific manner, and a combination of both protein
stability defects and lower catalytic activity may be required to
explain the clinical outcome of these rare metabolic diseases,
including TPI deficiency (Figure 4P).
4 | MATERIALS AND METHODS
4.1 | Generation of TPIIle170Val/Ile170Val mice
To create a vector for site-directed mutagenesis of mouse
TPI1, the wild type TPI1 locus composed from C57BL/6J
genomic DNA was PCR amplified and subcloned into an
E. coli backbone (pTretight2, Addgene 19407). PCR muta-
genesis was used to mutate codon 170 (ATT, encoding for
isoleucine) in exon 5 to GTT, encoding for valine. Then, a
loxP-flanked PGKneobpA cassette was introduced into the
NdeI site of TPI1 intron 4. The final vector was digested with
SalI and NotI to separate the mouse TPI locus from the vector
backbone, and transformed into the 129×C57BL/6J hybrid
embryonic stem cell line G4. One neomycin-resistant cell line
(2G5) was identified to have the integration on the TPI1 locus
and used to create a chimeric mouse. In brief, the cell line
was expanded, injected into blastocysts and transplanted.
Obtained chimera was crossed with Cre-recombinase-
expressing C57BL/6J mouse line to remove the neomycin
selection cassette. F1 littermates were tested for correct exci-
sion of the NEO+ marker by PCR and re-sequenced to verify
that only the mutation in exon 5, and one loxP site in intron
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4 was retained. This line was then backcrossed to the
C57BL/6J mouse line for nine generations.
4.2 | TPI activity assays
TPI activity was determined using a spectrophotometric
assay as previously described.29,38 Measurements were per-
formed at 2-3 different protein concentrations per tissue
lysate and repeated independently three times with freshly
dissected tissues from 20-week-old male mice. NADH loss
was measured using a Tecan M1000 PRO plate reader. TPI
activity was calculated at the point of maximal reaction rate
and normalized to lysate-free background activity.
4.3 | Western blotting
Protein lysates were prepared from dissected tissues from
20-week-old male mice and western blots were performed
using a polyclonal TPI serum (1:5000).39
4.4 | Substrate measurements
Immediately following dissection, tissues from 20-week-old
male mice were freeze clamped in liquid nitrogen and stored
at −80C. Tissues were ground to a fine powder over liquid
nitrogen and extracted in a mix of chloroform, methanol,
and water in a ratio of 40:40:20 with 0.1 M formic acid, as
previously described.40
The samples were analyzed by tandem mass spectrom-
etry on an Agilent 1290 liquid chromatography system
coupled to an Agilent 6470 triple quadrupole mass spec-
trometer. The LC-MS/MS method used was based on the
Agilent Metabolomics dMRM Database and Method with
a shortened chromatography. The compounds were
resolved on a C18 column (Zorbax RRHD Extend-C18,
2.1 × 100 mm, 1.8 μm; Agilent) with mobile buffer A1
(3% methanol, 10 mM tributylamine, 15 mM acetic acid),
mobile buffer B1 (10 mM tributylamine, 15 mM acetic
acid, 97% acetonitrile, 3% methanol), and mobile buffer
B2 (acetonitrile) by gradient elution at a constant column
temperature of 35C. The gradient program started with
100% A and a flow rate of 0.35 mL/min. The organic frac-
tion (B) was increased to 20% from 2 to 5 minutes and to
45% from 5 to 10 minutes. This was followed by a
2 minutes wash with 99% B1 and a 3 minutes wash of
99% B2 (1 mL/min) before returning to initial buffer con-
ditions for equilibration at a flow rate of 0.6 mL/min for
1 minute and at a flow rate of 0.35 mL/min for 2 minutes,
resulting in a total runtime of 18 minutes. The metabolites
were quantified by external calibration (Sigma-Aldrich
37442, G5251).
4.5 | Phenotypic screen
A cohort of 60 mice were phenotypically analyzed at the Ger-
man Mouse Clinic (GMC) in two standardized pipelines for sys-
tematic primary phenotyping as previously described,30,41 with
15 mice per group utilized for each test (equal numbers of male
and female, and mutant and wild-type animals). All animals
were age-matched within 2 weeks of each other and ranged
from 63 to 131 days old at the time of testing. All tests per-
formed were approved by the responsible authority in the United
Kingdom, as well as the district governments of Berlin and
Upper Bavaria, Germany, respectively.
All institutional and national guidelines for the care and
use of laboratory animals were approved by the responsible
authority in the United Kingdom, as well as the district gov-
ernments of Berlin and Upper Bavaria, Germany.
This manuscript does not contain studies with human
subjects performed by any of the authors.
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